A Granulocyte-Specific Protein S100A12 as a Potential Prognostic Factor Affecting Aggressiveness of Therapy in Patients with Juvenile Idiopathic Arthritis

Krzysztof Orczyk and Elzbieta Smolewska

Department of Pediatric Cardiology and Rheumatology, Medical University of Lodz, Sporna 36/50, 91-738 Lodz, Poland

Correspondence should be addressed to Elzbieta Smolewska; e.smolewska@wp.pl

Received 26 June 2018; Revised 16 September 2018; Accepted 25 September 2018; Published 22 October 2018

Guest Editor: Yi Zhao

Copyright © 2018 Krzysztof Orczyk and Elzbieta Smolewska. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Defining new prognostic biomarkers has become one of the most promising perspectives for the long-term care of patients with juvenile idiopathic arthritis (JIA). The new efficient indicators of disease activity and potential response to treatment are crucial in establishing new therapeutic plans in accordance with the “treat to target” strategy. One of the most studied proteins is called S100A12, which is an alarmin specific for granulocytes, considered as a marker of their activity.

Materials and Methods. Study involved 80 patients diagnosed with JIA. Children with systemic subtype were not included in the study. In 53 cases, blood samples were obtained in two time points. Results from the study group were compared to 29 age- and sex-matched healthy individuals.

Results. Serum S100A12 levels were higher in JIA than in healthy controls at the study baseline (11.67 ± 6.59 vs. 6.01 ± 2.33 ng/ml). There were no significant differences in S100A12 values between assessed subtypes of JIA. The highest concentrations were observed in patients within a disease flare. S100A12 levels were not dependent from using glucocorticosteroids. The studied protein appeared to be an efficient biomarker for JIA patients: 100% specificity as a diagnostic marker (cut-off level: 10.73 ng/ml) and 100% sensitivity as an indicator of exacerbations within a 3-month observation (cut-off level: 5.48 ng/ml).

Conclusions. S100A12 may become an important factor in influencing decisions on aggressiveness of JIA therapy. Further elaboration on the clinical algorithm is necessary for that protein to be included in everyday practice.

1. Background

1.1. Juvenile Idiopathic Arthritis. Juvenile idiopathic arthritis (JIA) is a heterogenous group of arthritides affecting children under 16 years of age. It should be suspected in patients with symptoms persisting for at least 6 weeks without an apparent cause [1]. Essential part of the diagnostic process involves eliminating arthropathies caused by the known etiological factors included in the so-called “list of exclusions” [2]. A lack of unequivocal clinical features or laboratory findings frequently results in the delay of the final diagnosis. According to Aoust et al. [3], JIA was suspected only in 37% of patients from the disease onset. The remaining patients were presenting symptoms for 3 months (on average) before being diagnosed with JIA.

1.2. Disease Activity. JIA patients may considerably differ from each other in terms of the severity of their disease. In the cohort study of 609 children reported by Guzman et al. [4], who analyzed disease activity and patients’ quality of life within a 5-year observation, four distinct types of JIA course were defined: mild (which is the most common, affecting 43.8% of patients), moderate (35.6%), severe controlled (9.0%), and severe persisting (11.5%). Taking into consideration the aforementioned classification, the adequate assessment of disease activity and response to treatment is crucial for effective long-term care of JIA patients.

Juvenile arthritis disease activity score (JADAS) is a widely used tool created to evaluate disease activity [5] in everyday practice of a pediatric rheumatologist. It contains four parameters: (1) physician global assessment, (2) patient or parent...
global assessment, (3) normalized value of erythrocyte sedimentation rate (ESR), and (4) active joint count. In the recent study, the version involving 27 joints (JADAS27) was utilized due to its simplicity and strong correlation with the entire assessment of 71 joints [6].

1.3. Treat to Target. The “treat to target” concept of therapy, which is recently applied in rheumatoid arthritis patients, has already attracted interest of pediatric rheumatologists as well [7]. According to this innovative approach, the aggressiveness of treatment should be associated with the therapeutic goal, which may be determined as clinical remission off medication or, if it does not seem achievable, as at least minimal disease activity [8].

Although the effectiveness of early aggressive therapy has been supported by the study of Wallace et al. [9], it may increase the risk of overtreatment in patients, who would have responded to less intensive and, by extension, less toxic therapy [10]. Ravelli et al. did not report significant difference in frequency of remission in patients with oligoarticular JIA treated with intraarticular glucocorticosteroids (GCS) in monotherapy (remission in 32%) or combined with methotrexate (remission in 37%) [11]. Blazina et al. [10] underscored the necessity of utilizing prognostic biomarkers in making decisions on aggressiveness of treatment.

1.4. “Classic” and New Biomarkers. “Classic” serological markers, which include rheumatoid factor (RF), anticyclic citrullinated peptide autoantibodies (ACPA), and antinuclear antibodies (ANA) [12], are helpful in assigning patients into separate JIA subtypes or estimating risk of comorbidities (such as uveitis). However, they do not provide sufficient data on disease activity or response to treatment to predict the future course of the disease. Therefore, more and more potential markers are studied in order to facilitate a long-term care of JIA patients. In a systematic review presented by Gohar et al. [13], there were 68 biomarkers evaluated in systemic JIA. Fifty of them were assessed by only a single research group. The authors postulated consolidation of findings and further validation of markers which are already identified. Thus, the recent study involved one of the most studied and the most promising biomarkers, which is called S100A12.

1.5. S100A12. S100A12, also known as calgranulin C, is one of the calcium-binding S100 family proteins. This alarmin is specific for granulocytes; therefore, it may be considered as an indicator of their activity [14]. It presents strong chemotactic activity as a ligand binding receptor for advanced glycation end products (RAGE) [15, 16], S100A12 participates in recruitment of inflammatory cells in murine models [17]. Previous findings reflect overexpression of S100A12 in inflamed tissues in adult patients with inflammatory bowel diseases, psoriatic arthritis, and rheumatoid arthritis [18, 19]. Moreover, serum concentration of S100A12 is considered as a marker of disease activity in children with Kawasaki disease [20].

Being an indicator of granulocytes’ activity, S100A12 may appear useful as a marker of disease activity in JIA patients. The S100A12 level in synovial fluid was 10 times higher than in serum in a study published by Foell et al. [21], which demonstrated its potential as a reliable marker of local inflammation. Furthermore, serum concentration of that protein was higher in patients with active arthritis than in children with stable remission. Baseline S100A12 levels were elevated in patients with good response to intraarticular GCS. Serum S100A12 concentrations were also increased in children who exacerbated within 6 months after measurement. Similar findings were reported by Yamaski et al., who observed higher S100A12 levels in patients who were unable to maintain remission for 2 years [22]. Additionally, S100A12 was the best isolated biomarker for prognosing disease flares in the further validation performed by Gerss et al. [23].

The most recent study by Gohar et al. [24] confirmed the relation between S100A12 concentration and the effectiveness of therapy. Patients with a good response to methotrexate and tumor necrosis factor (TNF) inhibitors had higher baseline S100A12 levels than treatment-refractory children. Combining methotrexate with systemic GCS did not affect the marker values. The authors suggested further elaboration on the ideal algorithm involving S100A12 in therapeutic decisions.

The present study was conducted in order to evaluate whether it is reliable to measure S100A12 serum levels in JIA patients in everyday practice of the pediatric rheumatologist. The objective of the study was to assess the clinical significance of S100A12 as a diagnostic biomarker of JIA and prognostic indicator of increasing disease activity within a 3-month observation.

2. Materials and Methods

The study involved 80 patients diagnosed with JIA who were admitted to the Department of Pediatric Cardiology and Rheumatology, Medical University of Lodz, Poland, between January 2017 and February 2018. In 53 cases, blood samples were collected in two time points (with an average interval of 102.4 ± 26.0 days) in order to evaluate dynamics of serum S100A12 concentrations. Patients diagnosed with systemic JIA were excluded from the study because of its distinct pathogenesis. Results from the study group were compared to the control group containing 29 age- and sex-matched individuals who were referred to the Department due to functional cardiovascular system dysfunction.

Patients’ records were comprehensively reviewed in order to build a database containing age at diagnosis and age at evaluation; JIA subtype according to International League of Associations for Rheumatology (ILAR) classification [2]; reason of admission (fresh diagnosis of JIA, disease flare, continuation of biological treatment, and check-up visit); active joint count; JADAS27 value and disease activity level determined using cut-off levels proposed by Consolaro et al. [25, 26] (patients with enthesitis-related arthritis were assessed with criteria for oligo- and polyarticular JIAs, depending on the active joint count); current therapy, including disease-modifying antirheumatic drugs, intraarticular and systemic GCS, and biological agents.
The study was approved by the Bioethics Committee of the Medical University of Lodz (approval no. RNN/31/17/KE).

3. Results

Characteristics of the study group are presented in Table 1. Serum S100A12 levels were significantly elevated in JIA patients at first time point (11.67 ± 6.59 ng/ml, P < 0.001) when compared to the control group (6.01 ± 2.33 ng/ml). Concentrations measured in the study group at second time point were also higher (7.45 ± 4.81 ng/ml) than in healthy individuals, but the difference did not reach statistical significance (P = 0.40). S100A12 values were independent from age at diagnosis (P = 0.899), age at the study baseline (P = 0.768), and sex (P = 0.534) of patients. They were also not related to “classic” serological markers. Moreover, levels of the protein did not differ (P = 0.121) between assessed subtypes of JIA (RF-positive polyarthritis was excluded from this part of analysis due to the small sample size).

Serum S100A12 concentrations were increased in JIA patients regardless of the reason of admission (Figure 1(a)). The highest values of S100A12 were observed in patients with disease flare, but the differences between subgroups of JIA patients were not statistically significant. S100A12 concentrations were significantly correlated with CRP (r = 0.473, P < 0.001) and ESR (r = 0.353, P < 0.001) values. In terms of the disease activity level (based on JADAS27), the most increased S100A12 concentrations were noted in patients with high disease activity (Figure 1(b)). However, that difference was not significant as well.

Apart from disease-modifying antirheumatic drugs (all patients in the study group were treated with methotrexate), forty-three JIA patients (53.8%) were using systemic GCS at first time point. Moreover, in twenty-four children (30.0%), intraarticular GCS were necessary during the first hospitalization within the study. However, S100A12 levels did not differ significantly (Figure 2) depending on usage of systemic or intraarticular GCS (P = 0.766 and P = 1.00, respectively). Nine patients were also treated with biological agents, but the significant difference in S100A12 levels was not observed (P = 0.0853).

Considering values noted at second time point, S100A12 levels increased in 14 patients (average change: 3.63 ± 3.50 ng/ml). Concurrent elevation of JADAS27 was observed in 2 (14.3%) patients. Concentrations of the marker decreased in 39 patients (average change: 7.23 ± 5.49 ng/ml). Simultaneous decline of JADAS27 was noted in 26 (66.7%) children. Differences in S100A12 levels between both time points were statistically significant (P < 0.001).

S100A12 had 100.0% specificity (95% CI: 88.1%—upper limit is not applicable) and 46.3% sensitivity (95% CI: 35.0–57.8%) as a diagnostic JIA biomarker for cut-off level 10.73 ng/ml with AUC 0.787 (95% CI: 0.701–0.873). The ROC curve is illustrated in Figure 3(a). S100A12 was also assessed as a potential prognostic marker for predicting exacerbations of the disease. It was characterized with

| Table 1: General characteristics of the study group. |
|-----------------------------------------------|
| 1st time point      | 2nd time point      |
|---------------------|---------------------|
| (n = 80)            | (n = 53)            |
| Female, n (%)       | 54 (67.5%)          | 36 (67.9%)          |
| Age at diagnosis (years) | 7.75 ± 4.27       | 7.57 ± 4.41         |
| Age at evaluation (years) | 10.40 ± 4.48      | 10.28 ± 4.58        |
| Reason of admission, n (%) |                |                    |
| Fresh diagnosis of JIA | 16 (20.0%)        | —                  |
| Disease flare        | 26 (32.5%)         | 11 (20.8%)          |
| Continuation of biological treatment | 9 (11.25%)       | 12 (22.6%)          |
| Check-up visit       | 29 (36.25%)        | 30 (56.6%)          |
| JIA subtypes, n (%)  |                    |                    |
| Oligoarticular JIA   | 54 (67.5%)         | 35 (66.0%)          |
| RF-negative polyarticular JIA | 11 (13.75%)    | 9 (17.0%)           |
| RF-positive polyarticular JIA | 1 (1.25%)      | 1 (1.9%)            |
| ERA                 | 14 (17.5%)         | 8 (15.1%)           |
| Clinical and laboratory features |            |                    |
| Fever on admission, n (%) | 9 (11.3%)        | 0 (0.0%)            |
| CRP > 5 mg/L, n (%)  | 13 (16.3%)         | 6 (11.3%)           |
| ESR > 20 mm/h, n (%) | 16 (20.0%)         | 4 (7.5%)            |
| Disease activity level (according to JADAS27), n (%) |            |                    |
| Clinically inactive disease | 19 (23.75%)     | 16 (30.2%)          |
| Minimal disease activity | 7 (8.75%)        | 12 (22.65%)         |
| Parent-acceptable symptom state | 5 (6.25%)     | 6 (11.3%)           |
| High disease activity | 49 (61.25%)       | 19 (35.85%)         |

JIA: juvenile idiopathic arthritis; RF: rheumatoid factor; ERA: enthesitis-related arthritis; JADAS27: juvenile arthritis disease activity score 27-joint reduced count.
S100A12 levels depending on (a) reason of admission and (b) disease activity level. P values were presented only for statistically significant comparisons. JIA: juvenile idiopathic arthritis.

**Figure 1:** S100A12 levels depending on (a) reason of admission and (b) disease activity level. P values were presented only for statistically significant comparisons. JIA: juvenile idiopathic arthritis.
100.0% sensitivity (95% CI: 71.5%—upper limit is not applicable), 21.4% specificity (95% CI: 10.3–36.8%), and AUC 0.372 (95% CI: 0.203–0.542) as an indicator of disease flare within a 3-month observation (Figure 3(b)).

4. Discussion

Personalized treatment involving the “treat to target” strategy opens a new chapter in the therapeutic approach in JIA patients. Effectiveness of such therapy can be maximized by reliable assessment of disease activity, both in patients presenting symptoms and in children achieving clinical remission on medication. One of the potential diagnostic and prognostic biomarkers, S100A12 protein, was included in our study in order to evaluate its clinical significance.

Serum S100A12 levels were significantly higher in JIA patients when compared to healthy individuals. These results are consistent with findings of Foell et al. [21]
and Bojko [27]. Unlike Yamasaki et al. [22], we did not observe significant differences in S100A12 values between included JIA subtypes. However, the remarkable specificity of S100A12 (100% for cut-off value 10.73 ng/ml) suggests potential utilization of that biomarker in differential diagnosis in patients suspected of JIA.

Serum S100A12 concentrations were noticeably increased in patients with high disease activity. The hundred-percent sensitivity in predicting disease flare within a 3-month observation (cut-off value 5.48 ng/ml) supports findings of the previous study by Gerss et al. [23]. As reported by Gohar et al. [24], S100A12 values were independent from GCS intake, which makes that protein a reliable prognostic marker in patients who need to use them. In our study group, more than a half of JIA patients were taking systemic GCS at the study baseline.

Although S100A12 is postulated as an indicator of treatment response [24], decrease of its serum concentration was related to the decline in the JADAS27 value only in 66.7% of patients. Therefore, it should not be considered as an isolated marker of the effectiveness of therapy. On the other hand, Giancane et al. [28] stated that the pain should be considered as a direct cause and main indication for treatment in JIA patients. Older age at diagnosis and longer disease duration are the risk factors of lower disease activity. Smartphone applications should be elaborated on in order to get the better feedback from the patient [28, 30].

The main limitation of the study was the considerable diversity of the study group. A reliable assessment of effectiveness of treatment and measurements of potential biomarker values should be performed in a possibly homogenous group of patients independent from factors influencing the results. Additionally, the findings from the study group should be compared with patients with arthritides other than JIA in order to evaluate the usefulness of S100A12 in differential diagnosis.

5. Conclusions

Including S100A12 protein in everyday practice of the pediatric rheumatologists might be helpful in making therapeutic decisions. Escalation of aggressiveness of therapy in the right group of patients may potentially reduce the frequency of disease flares. Setting the clinical algorithm of ordering the S100A12 test is challenging until it becomes widely accessible in clinical laboratories.

Data Availability

The data used to support the findings of this study are included within the article.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

This study was supported by the grant No. 503/8-000-04/503-81-002-17 from Medical University of Lodz, Poland.

References

[1] V. Opoka-Winiarska, Z. Żuber, and E. Smolewska, “Diagnostyka i leczenie młodzieńczego idiopatycznego zapalenia stawów–praktyczne wskazówki dla pediatry,” Pediatria po Dyplomie, vol. 21, no. 3, pp. 6–18, 2017.
[2] R. E. Petty, T. R. Southwood, P. Manners et al., “International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001,” The Journal of Rheumatology, vol. 31, no. 2, pp. 390–392, 2004.
[3] L. Aoust, L. Rossi-Semerano, I. Koné-Paut, and P. Dusser, “Time to diagnosis in juvenile idiopathic arthritis: a French perspective,” Orphanet Journal of Rare Diseases, vol. 12, no. 1, p. 43, 2017.
[4] J. Guzman, A. Henrey, T. Loughin et al., “Predicting which children with juvenile idiopathic arthritis will have a severe disease course: results from the ReACCh-Out cohort,” The Journal of Rheumatology, vol. 44, no. 2, pp. 230–240, 2017.
[5] A. Consolaro, N. Ruperto, A. Bazso et al., “Development and validation of a composite disease activity score for juvenile idiopathic arthritis,” Arthritis and Rheumatism, vol. 61, no. 5, pp. 658–666, 2009.
[6] A. Bazso, A. Consolaro, N. Ruperto et al., “Development and testing of reduced joint counts in juvenile idiopathic arthritis,” The Journal of Rheumatology, vol. 36, no. 1, pp. 183–190, 2009.
[7] A. Ravelli, A. Consolaro, G. Horneff et al., “Treating juvenile idiopathic arthritis to target: recommendations of an international task force,” Annals of the Rheumatic Diseases, vol. 77, no. 6, pp. 819–828, 2018.
[8] C. Hinze, F. Gohar, and D. Foell, “Management of juvenile idiopathic arthritis: hitting the target,” Nature Reviews Rheumatology, vol. 11, no. 5, pp. 290–300, 2015.
[9] C. A. Wallace, E. H. Giannini, S. J. Spalding et al., “Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis,” Arthritis and Rheumatism, vol. 64, no. 6, pp. 2012–2021, 2012.
[10] Š. Blazina, G. Markelj, M. Z. Avramovič, N. Toplak, and T. Avčin, “Management of juvenile idiopathic arthritis: a clinical guide,” Paediatric Drugs, vol. 18, no. 6, pp. 397–412, 2016.
[11] A. Ravelli, S. Davi, G. Braccioli et al., “Intra-articular corticosteroids versus intra-articular corticosteroids plus methotrexate in oligoarticular juvenile idiopathic arthritis: a multicentre, prospective, randomised, open-label trial,” Lancet, vol. 389, no. 10072, pp. 909–916, 2017.
[12] Y. Wang, F. Pei, X. Wang, Z. Sun, C. Hu, and H. Dou, “Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody for juvenile idiopathic arthritis,” Journal of Immunology Research, vol. 2015, Article ID 915276, 12 pages, 2015.
[13] F. Gohar, C. Kessel, M. Lavric, D. Holzinger, and D. Foell, “Review of biomarkers in systemic juvenile idiopathic arthritis:
helpful tools or just playing tricks?,” *Arthritis Research & Therapy*, vol. 18, no. 1, p. 163, 2016.

[14] T. Vogl, C. Pröpper, M. Hartmann et al., “S100A12 is expressed exclusively by granulocytes and acts independently from MRP8 and MRP14,” *The Journal of Biological Chemistry*, vol. 274, no. 36, pp. 25291–25296, 1999.

[15] M. A. Hofmann, S. Drury, C. Fu et al., “RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides,” *Cell*, vol. 97, no. 7, pp. 889–901, 1999.

[16] M. A. Hofmann, S. Drury, B. I. Hudson et al., “RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response,” *Genes and Immunity*, vol. 3, no. 3, pp. 123–135, 2002.

[17] P. Rouleau, K. Vandal, C. Ryckman et al., “The calcium-binding protein S100A12 induces neutrophil adhesion, migration, and release from bone marrow in mouse at concentrations similar to those found in human inflammatory arthritis,” *Clinical Immunology*, vol. 107, no. 1, pp. 46–54, 2003.

[18] D. Foell, D. Kane, B. Bresnihan et al., “Expression of the proinflammatory protein S100A12 (EN-RAGE) in rheumatoid and psoriatic arthritis,” *Rheumatology*, vol. 42, no. 11, pp. 1383–1389, 2003.

[19] D. Foell, T. Kucharzik, M. Kraft et al., “Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease,” *Gut*, vol. 52, no. 6, pp. 847–853, 2003.

[20] D. Foell, F. Ichida, T. Vogl et al., “S100A12 (EN-RAGE) in monitoring Kawasaki disease,” *Lancet*, vol. 361, no. 9365, pp. 1270–1272, 2003.

[21] D. Foell, H. Wittkowski, I. Hammerschmidt et al., “Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations,” *Arthritis and Rheumatism*, vol. 50, no. 4, pp. 1286–1295, 2004.

[22] Y. Yamasaki, S. Takei, H. Imanaka et al., “Prediction of long-term remission of oligo/polyarticular juvenile idiopathic arthritis with S100A12 and vascular endothelial growth factor,” *Modern Rheumatology*, vol. 26, no. 4, pp. 551–556, 2016.

[23] J. Gerss, J. Roth, D. Holzinger et al., “Phagocyte-specific S100 proteins and high-sensitivity C reactive protein as biomarkers for a risk-adapted treatment to maintain remission in juvenile idiopathic arthritis: a comparative study,” *Annals of the Rheumatic Diseases*, vol. 71, no. 12, pp. 1991–1997, 2012.

[24] F. Gohar, J. Anink, H. Moncrieffe et al., “S100A12 is associated with response to therapy in juvenile idiopathic arthritis,” *The Journal of Rheumatology*, vol. 45, no. 4, pp. 547–554, 2018.

[25] A. Consolaro, G. Braccioli, N. Rupert et al., “Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: defining criteria based on the juvenile arthritis disease activity score,” *Arthritis and Rheumatism*, vol. 64, no. 7, pp. 2366–2374, 2012.

[26] A. Consolaro, N. Rupert, G. Braccioli et al., “Defining criteria for high disease activity in juvenile idiopathic arthritis based on the juvenile arthritis disease activity score,” *Annals of the Rheumatic Diseases*, vol. 73, no. 7, pp. 1380–1383, 2014.

[27] J. Bojko, “Measurement of blood calprotectin (MRP-8/MRP-14) levels in patients with juvenile idiopathic arthritis,” *Rheumatologia*, vol. 1, pp. 18–22, 2017.

[28] G. Giancane, A. Alongi, S. Rosina, S. Calandra, A. Consolaro, and A. Ravelli, “Open issues in the assessment and management of pain in juvenile idiopathic arthritis,” *Clinical and Experimental Rheumatology*, vol. 35, Supplement 107, pp. S123–S126, 2017.

[29] A. Rashid, L. Cordingley, R. Carrasco et al., “Patterns of pain over time among children with juvenile idiopathic arthritis,” *Archives of Disease in Childhood*, vol. 103, no. 5, pp. 437–443, 2018.

[30] R. A. Cai, D. Beste, H. Chaplin et al., “Developing and evaluating JIAApp: acceptability and usability of a smartphone app system to improve self-management in young people with juvenile idiopathic arthritis,” *JMIR mHealth and uHealth*, vol. 5, no. 8, article e121, 2017.